DIN 02553627 — BIMZELX 320 MG
BIMZELX is a solution of Bimekizumab marketed by UCB CANADA INC. The full Bimekizumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02553627
- Brand name
- BIMZELX
- Active ingredient
- Bimekizumab
- Strength
- 320 MG
- Dosage form
- SOLUTION
- Route
- SUBCUTANEOUS
- Manufacturer
- UCB CANADA INC
- Health Canada status
- MARKETED
- Drug class
- Interleukin-17A/F inhibitor (IL-17 antibody)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Bimekizumab products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02525267 | BIMZELX | 160 MG | SOLUTION | UCB CANADA INC | MARKETED |
| 02525275 | BIMZELX | 160 MG | SOLUTION | UCB CANADA INC | MARKETED |
| 02553619 | BIMZELX | 320 MG | SOLUTION | UCB CANADA INC | MARKETED |